Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CXCR3 | P49682 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6409808 | 0.87 | SMN1; SMN2 (0.48) | KDM4ESMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL2400849 | 0.87 | MEN1 (0.53) | KDM4ESMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL6410166 | 0.84 | KDM4E (0.62) | KDM4ESMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL6410169 | 0.76 | KDM4E (0.59) | KDM4ESMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL2401328 | 0.76 | GAA (0.34) | MEN1KMT2A | |
| SCHEMBL29040265 | 0.71 | SMN1; SMN2 (0.82) | KDM4ESMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL11623286 | 0.71 | SMN1; SMN2 (0.82) | KDM4ESMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL6667166 | 0.69 | SMN1; SMN2 (0.79) | KDM4ESMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL7756182 | 0.69 | SMN1; SMN2 (0.79) | KDM4ESMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL1298199 | 0.69 | SMN1; SMN2 (1.00) | KDM4ESMN1; SMN2MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224172-A1 | Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods | GRUENENTHAL GMBH (DE) | 2011-09-15 | — | — | US | claimed |
| US-8048890-B2 | Analgesics; neuropathic pain; headaches; muscle relaxants; incontence; tinnitus; diarrhea; antiarrhythmia agents; antiischemic agents; antiinflammatory agents; antiulcer agents; antidepressants; antiepileptic agents | GRUENENTHAL GMBH (DE) | 2011-11-01 | — | — | US | disclosed |
| US-20110224172-A1 | Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods | GRUENENTHAL GMBH (DE) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224172-A1 | Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods | SULT1E1, DECR1, CYP8B1 | KDM4E 356/4885SMN1; SMN2 1407/4885MEN1 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.